These results suggest that FABP3 may be used as a mechanistic biomarker and the potential therapeutic target in the atrial metabolic dysregulation with subsequent atrial remodeling and/or chronic atrial dysfunction related to obesity. This evidence concerns the gene FABP3 and obesity due to melanocortin 4 receptor deficiency.